繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

RedHill Bizerma称Opaganib因神经母细胞瘤获得FDA孤儿药称号

2024-08-26 19:38

07:38 AM EDT, 08/26/2024 (MT Newswires) -- RedHill Biopharma (RDHL) said Monday that the US Food and Drug Administration granted orphan drug designation for opaganib as a treatment for neuroblastoma, a type of childhood cancer.

Besides accelerated review, the designation provides opaganib a seven-year exclusivity period in the neuroblastoma market if the drug is approved, according to Redhill.

The company's shares were up 1.1% in recent premarket activity.

Price: 9.12, Change: +0.10, Percent Change: +1.11

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。